Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eosinophilic

- PMLiVE

EMA starts contraceptive safety probe

Follows French investigation into Bayer’s Diane 35

- PMLiVE

Takeda gets FDA approval for alogliptin franchise in diabetes

Comprises Nesina, Oseni and Kazano

Novartis building

Novartis withdraws application for Ruvise approval in EU

Had submitted imatinib mesylate for use in hypertension

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

Teva suffers setback as Nuvigil fails late-stage trial

Disappointing results in treating bipolar disorder but drug development continues

- PMLiVE

EMA publishes marketing application guidance for pharma

Aims to clarify what to include in summaries of product characteristics

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

Allergan gets US approval for Botox in overactive bladder

Could add $200m to annual sales

- PMLiVE

Santhera’s Raxone turned down for rare eye condition

EMA concerned about drug's ability to improve eyesight

- PMLiVE

EMA recommends suspension of Merck’s Tredaptive

Pharma company had already anticipated decision by withdrawing product worldwide

- PMLiVE

FDA approves first egg-free flu vaccine Flublok

Insect virus production method means more vaccine can be produced at a faster rate

- PMLiVE

FDA fast tracks two new lung cancer drugs

Boehringer’s afatinib and Roche/Astellas’ Tarveca receive accelerated review process

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links